The company says the early trial of its hair-loss therapy saw patients benefit from six times more hair growth than placebo.

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

Ryght AI has announced a strategic collaboration with QPS Holdings for optimising clinical trial processes globally.

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

BIAL has completed the full dose regimen for the first subject in the Phase II ACTIVATE trial of BIA 28-6156, for Parkinson's treatment.

J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over competitors’ more frequent regimens.

VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel for treating non-segmental vitiligo.

Data from the largest US Lyme disease registry suggests that 90% of PLD patients are excluded from clinical trials.

The US Food and Drug Administration has issued guidance urging sponsors and trial sites to consider the necessity of the invasive procedure.

CytoMed Therapeutics has signed a business and research collaboration agreement with SunAct Cancer Institute for a clinical trial in India.

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.